Orphan drug monopolies extended 180 days—named after someone Congress won't name

What it does

This bill extends the market-exclusivity periods for orphan drugs (medicines for rare diseases) by 180 days if the drug was developed during the COVID-19 emergency period (December 1, 2019 through 120 days before the federal emergency ends). Orphan drugs already receive long exclusivity periods (5–12 years depending on the type) to incentivize development of treatments for small patient populations; this bill adds six months to those periods as compensation for pandemic-related development delays. The primary beneficiaries are pharmaceutical companies developing orphan drugs, which gain extended periods of market protection and pricing power.

Why we flagged it

The bill's operative mechanism is a 180-day extension of market-exclusivity periods for orphan drugs developed during COVID-19. This is a direct subsidy to pharmaceutical manufacturers in the form of extended pricing power, framed as pandemic relief but functioning as a permanent regulatory carve-out.

What the text implies

• The bill does not define 'covered orphan drug' by reference to actual pandemic delay—it applies to ANY orphan drug with an application submitted during the COVID-19 emergency period, regardless of whether development was actually disrupted. This creates a blanket subsidy rather than targeted relief.
• Extension of exclusivity periods directly increases drug prices for patients and public payers (Medicare, Medicaid) by delaying generic competition. The bill contains no price-control, transparency, or reinvestment requirement.
• The bill's title 'Leo's Law' and the 'for other purposes' clause suggest a commemorative or personal legislative vehicle, but the text does not explain who Leo is or why this specific drug-monopoly extension honors that person.
• The 180-day extension applies to multiple overlapping exclusivity periods (12-year, 5-year, 3-year, 7-year, and patent-delay periods), potentially stacking extensions and creating longer-than-stated monopoly periods for some drugs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients with rare diseases may benefit from continued incentives for orphan-drug development, but the mechanism—extending monopoly pricing periods—is a private subsidy that increases costs for patients, insurers, and public programs (Medicare, Medicaid) without direct public return. The bill does not require price controls, transparency, or reinvestment of extended-monopoly profits into research.

Who stands to gain

• pharmaceutical companies developing orphan drugs
• biopharmaceutical manufacturers

Named in the bill

FDA, HHS, pharmaceutical industry, orphan drug developers, Medicare, Medicaid

Where it stands

1 cosponsor: 1 Republicans.

• Feb 25, 2026 — Introduced · Congress.gov: “Introduced in House”
• Feb 25, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.